Mavixen (Glecaprevir + Pibrentasvir) Tablets

Indicated for the treatment of chronic Hepatitis C (CHC) in adults and adolescents:

• 🦠 Pan-Genotypic: Approved for Genotypes 1, 2, 3, 4, 5, and 6.
• 🏥 Renal Impairment: Safe for use in patients with any degree of renal impairment (CKD).
• 💊 Retreatment: Effective for patients who have failed prior treatments (DAA-experienced).

Packaging: 21 tablets per bottle (1-week supply).

⚠️ ADMINISTRATION PROTOCOL:

• 💊 Dose: Take 3 tablets at once, once daily. Total daily dose: 300 mg Glecaprevir / 120 mg Pibrentasvir.
• 🍔 With Food: Must be taken with food to ensure proper absorption.
• 📅 Duration: Standard course is 8 weeks (8 bottles). Duration may be 12 or 16 weeks for patients with cirrhosis or specific prior treatment failures.

• Severe hepatic impairment (Child-Pugh C).
• Co-administration with Atazanavir or Rifampin.
• Pregnancy and breastfeeding.
• Use of ethinyl estradiol-containing contraceptives (may increase liver enzymes).

Mavixen is generally well-tolerated. Common adverse reactions include:

• 🤯 Neurological: Headache.
• 💤 General: Fatigue.
• 🤢 Gastrointestinal: Nausea (mitigated by taking with food).
• Pruritus (itching) is rare but possible.